Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Thermo Fisher Sells Businesses Before Purchase of Life Technologies

By LabMedica International staff writers
Posted on 21 Jan 2014
On January 6, 2014, Thermo Fisher Scientific (Waltham, MA, USA) announced a USD 1.06 billion sale of multiple business units to GE Healthcare (Little Chalfont, United Kingdom), as a condition of regulatory approval for Thermo Fisher's acquisition of Life Technologies (Carlsbad, CA, USA). More...


The businesses sold to General Electric's life sciences arm include Thermo Fisher's cell culture, gene modulation, and magnetic beads units, which Thermo Fisher believes to have generated a combined USD 250 million in revenue over the past year. Goldman Sachs analysts said they do not expect the deal to have a major impact on Thermo Fisher's continued growth.

The divestiture has been expected since November 2013 when Thermo Fisher announced that it had reached an agreement with the European Commission to approve the purchase of Life Technologies.

If not for the sales announced on January 16, 2014, the acquisition would have left Thermo Fisher with almost 50% of the cell culture market. In the US, the Federal Trade Commission (FTC) approval for the Life Technologies purchase is still pending, but Thermo Fisher has stated that they do not expect the FTC to raise any additional hurdles.

In the genomics world, the USD 13.6 billion acquisition of Life Technologies has focused on Life's Ion Torrent arm, the gene sequencing unit that has been making gains against market leader Illumina. Ion Torrent has been noted for its rapid development and heavy investments in R&D, including a yet-unreleased semiconductor chip for the Ion Proton sequencer that could make the instrument competitive in high-throughput sequencing with Illumina's HiSeq 2500.

Thermo Fisher has the resources to pour even more funding into the Ion Torrent line. However, it is unknown what the new parent company's intentions are for Life Technologies, which has a huge portfolio of biotechnology products, any number of which will fit into Thermo Fisher's existing pipelines in sample prep, synthetic biology, forensics, and other research and clinical applications. Thermo Fisher is not known for its emphasis on R&D; in fact, in recent years, the smaller Life Technologies has occasionally outspent Thermo Fisher in this area.

Related Links:

Thermo Fisher Scientific
GE Healthcare
Life Technologies



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.